Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
Aims to boost speed & precision in patient care
The transition from an outsourced MRI model to an in-house facility marks more than an infrastructure upgrade
Minimally invasive laser-based procedure restores blood flow in complex arterial blockage, enables next-day discharge and improved mobility
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Subscribe To Our Newsletter & Stay Updated
